ライフサイエンスコーパス: PET imaging

1 gate glucose utilization of BAT by (18)F-FDG PET imaging.

2 in healthy adult mice by dynamic and static PET imaging.

3 ikely to be achieved by the sole use of TSPO PET imaging.

4 p between fcMRI and both Tau-PET and amyloid-PET imaging.

5 vo radiography as well as static and dynamic PET imaging.

6 value was determined with the HEC method at PET imaging.

7 racer for investigating tumor perfusion with PET imaging.

8 Bs)-were studied with whole-body (11)C-ER176 PET imaging.

9 h(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)) for PET imaging.

10 well with the behavior observed by standard PET imaging.

11 tracer uptake was assessed by (18)F-AH113804 PET imaging.

12 tivity MRI (fcMRI) in the context of amyloid-PET imaging.

13 s evaluated by (99m)Tc-MIBI SPECT /(18)F-FDG PET imaging.

14 ostic efficacy of beta-amyloid (Abeta) brain PET imaging.

15 8)F-FVIIai in the tumors measured in vivo by PET imaging.

16 2-deoxy-2-[F-18]fluoro-D-glucose ((18)F-FDG) PET imaging.

17 nt of NOD's elimination kinetics by means of PET imaging.

18 (41 women and 20 men) who underwent amyloid PET imaging.

19 s synthesized to incorporate fluorine-18 for PET imaging.

20 exposure to healthy tissues during repeated PET imaging.

21 asured in patients during [18F]FMISO and 15O PET imaging.

22 quence NLys-Lys-Pro-Tyr-Tle-Leu suitable for PET imaging.

23 fragments and have ideal characteristics for PET imaging.

24 51)Cr-GFR), using serial plasma sampling and PET imaging.

25 ed the feasible application of (64)Cu(I) for PET imaging.

26 ghrelin receptor expressing carcinomas using PET imaging.

27 (68)Ga-DOTATOC (an sst receptor agonist), in PET imaging.

28 ale, retired breeder Sprague-Dawley rats for PET imaging.

29 the in vivo status of DLL3 expression using PET imaging.

30 s-3 HABs, 3 MABs, and 2 LABs-underwent brain PET imaging.

31 all cerebral emboli were detected in vivo by PET imaging.

32 se model of bleomycin-induced fibrosis using PET imaging.

33 o underwent amyloid PET and MRI, but not tau PET imaging.

34 ets while significantly reducing the cost of PET imaging.

35 ng PDE4B-preferring radioligand for clinical PET imaging.

36 tic resonance imaging but not tau or amyloid PET imaging.

37 uclide with a half-life of 12.7 h, ideal for PET imaging.

38 d B (11C-PiB) positron emission tomographic (PET) imaging.

39 le for in vivo positron emission tomography (PET) imaging.

40 d non-invasive positron emission tomography (PET) imaging.

41 tory motion in positron emission tomography (PET) imaging.

42 8)F for use in positron-emission tomography (PET) imaging.

43 (18)F-FDS were determined by dynamic 35-min PET imaging (15 frames x 8 s, 26 frames x 30 s, 20 frame

44 , in the tracer concentration range used for PET imaging, [(18)F]CFA is primarily a substrate for dCK

45 y (1.) in-beam positron-emission tomography (PET) imaging; (2.) intracardiac voltage mapping with vis

46 ge, 12.2 y; age range, 6.8-19.1 y) underwent PET imaging; 25 (74%) had localized disease.

47 post-myocardial infarction period, (18)F-FDG PET imaging after a single bolus administration may unde

48 Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising wit

49 to determine the feasibility of the hypoxia PET imaging agent (64)Cu-ATSM to detect hypoxia in a rab

50 The new immuno-PET imaging agent (89)Zr-DFO-AMG102 was successfully syn

51 oss species of [(18) F]Nifene, a fast acting PET imaging agent for alpha4beta2* nAChRs.

52 A same-day PET imaging agent for measuring PD-L1 status in primary

53 usion:(64)Cu-DOTA-alendronate is a promising PET imaging agent for the sensitive and specific detecti

54 nce that (64)Cu-NOTA-RamAb can function as a PET imaging agent for visualizing VEGFR-2 expression in

55 A CD3 PET imaging agent targeting T cells was synthesized to t

56 as modified for use as a (89)Zr-based immuno-PET imaging agent to noninvasively determine the local l

57 JR11 is under clinical development as a PET imaging agent when labeled with (68)Ga ((68)Ga-NODAG

58 te as a mammary microcalcification-targeting PET imaging agent, using an ideal rat model.

59 for translational work in humans as an AT1R PET imaging agent.

60 sing its potential use as a MMP-13 targeting PET imaging agent.

61 ose within the acceptable range for clinical PET imaging agents and the potential for translation int

62 Novel PET imaging agents for assessing vascular endothelial gr

63 ted for use as positron emission tomography (PET) imaging agents for prostate cancer.

64 Positron emission tomography (PET) imaging agents that detect amyloid plaques containi

65 PET imaging allowed for the sensitive detection of DIPG

66 Furthermore, PET imaging allows better quantification than the SPECT

67 In parallel, PET imaging allows quantitative assessment of the spatia

68 Positron Emission Tomography (PET) imaging allows the estimation of multiple aspects o

69 ugh followed in 2011 with (68)Ga-PSMA-11 for PET imaging and (131)I-MIP-1095 for endoradiotherapy of

70 -18 is the most widely used radioisotope for PET imaging and a thorough overview of the available rad

71 tter (P < 0.05-0.001) than (18)F-FDG through PET imaging and biodistribution studies in MDA-MB-231 an

72 ynthesized to target CA125 and evaluated via PET imaging and biodistribution studies in mice bearing

73 PET imaging and biodistribution studies showed fast clea

74 PET imaging and biodistribution studies showed that inje

75 PET imaging and biodistribution studies were performed i

76 ntly better than (18)F-FDG, as shown through PET imaging and biodistribution studies.

77 PET imaging and biodistribution were performed 24 h afte

78 ition and neuroinflammation, we used in vivo PET imaging and ex vivo autoradiography with Pittsburgh

79 In vivo PET imaging and ex vivo biodistribution studies in mice

80 In vivo PET imaging and ex vivo biodistribution studies were per

81 PET imaging and ex vivo biodistribution studies with (18

82 s a promising bimodal ligand for noninvasive PET imaging and intraoperative optical imaging of GRPr-e

83 macokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input func

84 aging probe that can be used for noninvasive PET imaging and optical imaging of prostate cancer.

85 te that our mouse model permits longitudinal PET imaging and quantification of T-cell homing during i

86 escent-labeled (68)Ga-tilmanocept allows for PET imaging and real-time intraoperative detection of SL

87 ecule cysteine cathepsin probes for clinical PET imaging and suggest that they have the potential to

88 n low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on

89 We observed specific and simultaneous PET imaging and treatment of tumors in this preclinical

90 apy (PDT) with positron emission tomography (PET) imaging and internal radiotherapy (RT).

91 labeled version, (64)Cu-NOTA-PEG4-cRGD2, for PET imaging, and a fluorescent version, FITC-PEG4-cRGD2,

92 tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disea

93 eficient mice were used for biodistribution, PET imaging, and determination of in vivo metabolization

94 ND AND Amyloid-positron emission tomography (PET) imaging (API) detects amyloid-beta pathology early

95 PSMA PET imaging appears to outperform traditional imaging in

96 eneic DLBCL mouse model, this PARP1-targeted PET imaging approach allowed us to discriminate between

97 Our PARP1-targeted PET imaging approach may be an attractive addition to th

98 [18F]AV-1451) positron emission tomographic (PET) imaging are linked with clinical phenotype and cort

99 w is to report on the value of (11)C-choline PET imaging as a diagnostic procedure for metastasis-dir

100 views the current evidence of ERalpha and PR PET imaging as predictive and early-response biomarkers

101 FTP and [(11)C]Pittsburgh compound B PET imaging as well as MRI were performed in seven patie

102 -hydroxyephedrin ((11)C-HED) and (15)O-water PET imaging at rest and after exposure to mild cold (16

103 -hydroxyephedrin ((11)C-HED) and (15)O-water PET imaging at rest and after exposure to mild cold (16

104 They all underwent [F-18]-AV-1451 PET imaging before death.

105 ed for biomarker development, with (18)F-FDG PET imaging being the most studied.

106 PET imaging, biodistribution, and dosimetry studies in m

107 PET imaging, biodistribution, autoradiography and immuno

108 There are several PET imaging biomarkers for Abeta including (11)C-PiB and

109 Test-retest PET imaging, blocking with AT1R antagonist candesartan (

110 For PET imaging, both (68)Ga- and (18)F-labeled agents have

111 (18)F-florbetaben PET imaging can accurately identify and differentiate be

112 Overall, our results suggest granzyme B PET imaging can serve as a quantitatively useful predict

113 Conclusion PET imaging characteristics associated with distant meta

114 Quantitative PET imaging characteristics including statistical, histo

115 In vivo PET imaging clearly visualized PD-L1 expression in mice

116 he quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to ensure the comparability of PE

117 Furthermore, PET imaging confirmed that ccRCC tumors exhibited increa

118 e uptake of (18)F-FVIIai measured in vivo by PET imaging correlated (r = 0.72, P < 0.02) with TF prot

119 Furthermore, the results showed that PET imaging could be reliably used to monitor early trea

120 plied mathematical modeling to Abeta in vivo PET imaging data to investigate competing theories of Ab

121 alpha-(11)C-methyl-l-tryptophan ((11)C-AMT) PET imaging demonstrated increased tryptophan uptake and

122 PET imaging demonstrated rapid uptake of tracer in the P

123 sonance imaging (MRI) experiments, Macroflor PET imaging detects changes in macrophage population siz

124 clinical trial was initiated to compare the PET imaging diagnostic potential of (18)F-4FMFES with th

125 Conclusion: Because of highly sensitive PET imaging even of tissues with low alphavbeta6 integri

126 Because of highly sensitive PET imaging even of tissues with low alphavbeta6 integri

127 PET imaging exhibited high kidney-to-blood contrast and

128 ges in management resulting from PSMA ligand PET imaging for both biochemical recurrence and primary

129 Specificity of (68)Ga-PSMA HBED-CC PET imaging for PET-positive LNs was defined by comparis

130 spected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of (

131 spected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of (

132 sburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Abeta.

133 451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11

134 e number of publications about PSMA-targeted PET imaging from 2013 to 2016 (e.g., a search of the Web

135 (89)Zr-MSB0010853 PET imaging gives insight into the in vivo behavior of M

136 For primary PC, PSMA ligand PET imaging has been shown to be superior to cross-secti

137 The current research-based evidence on PET imaging has demonstrated encouraging potential in th

138 ed that chelator-mediated nanoparticle-based PET imaging has its inherent drawbacks and can possibly

139 Hence, the increasing popularity of TSPO PET imaging has paradoxically introduced substantial unc

140 (68)Ga-labeled somatostatin receptor ligand PET imaging has recently been shown in preclinical and e

141 PET imaging has the potential to detect striatal molecul

142 ose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLBCL i

143 l and synthetic amino acids radiolabeled for PET imaging have been investigated in prostate cancer pa

144 uman myeloid sarcoma, we monitored by Immuno-PET imaging human central memory T cells (TCM), which we

145 Here we used PET imaging in 40 healthy adults to compare, within indi

146 ATATE PET imaging was compared to [(18)F]FDG PET imaging in 42 patients with atherosclerosis.

147 ization before radiolabeling with (64)Cu for PET imaging in an apolipoprotein E-deficient (ApoE(-/-))

148 )Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

149 )Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

150 quent longitudinal change in Abeta using PIB-PET imaging in cognitively normal older adults.

151 PET imaging in mice revealed distinctly high tumor/backg

152 ands were compared using biodistribution and PET imaging in murine models of pancreatic cancer.

153 PET imaging in non-human primates confirms that this rad

154 ed using ex vivo biodistribution and in vivo PET imaging in non-tumor-bearing animals as well as in K

155 Tissue metabolite analysis in rodents and PET imaging in nonhuman primates under baseline and bloc

156 ntal and neurodegenerative mouse models with PET imaging in patients with recent-onset schizophrenia

157 We tested the feasibility of (18)F-FDS renal PET imaging in rats.

158 ful tool to interrogate MYC via TfR-targeted PET imaging in TNBC.

159 n Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice.

160 sed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-sensitive COLO205 and treatment

161 sed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-sensitive COLO205 and treatment

162 ory gating in positron emission tomographic (PET) imaging in a clinical trial comparing conventional

163 verview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretat

164 The current standard for breast PET imaging is (18)F-FDG.

165 (68)Ga-PSMA HBED-CC PET imaging is a promising method for early detection of

166 he [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and n

167 PET imaging is a widely applicable but a very expensive

168 Whether seizures also affect (18)F-FET PET imaging is currently unknown.

169 (18)F-FDG PET imaging is routinely used to investigate brown adipo

170 At present, (18)F-FDG PET imaging is the most widely used clinical tool for me

171 Amyloid positron emission tomography (PET) imaging is a valuable tool for research and diagnos

172 ocator-protein positron emission tomography (PET) imaging, is increased in unmedicated persons presen

173 We envision that SCN5A measurements using PET imaging may serve as a novel diagnostic tool to stra

174 formance more accurately than other fMRI and PET imaging measures.

175 e early symptomatic state and if [(18)F]MPPF PET imaging might be a promising biomarker of early dege

176 adiation dose from whole-body (11)C-nicotine PET imaging of 11 healthy (5 male and 6 female) subjects

177 For PET imaging of 18-kDa translocator protein (TSPO), a bio

178 [18F]F-AraG PET imaging of a murine aGVHD model enabled visualizatio

179 PET imaging of amino acid transport using O-(2-(18)F-flu

180 Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performe

181 (18)F-FLT PET imaging of breast cancer after 1 cycle of NAC weakly

182 e feasibility of a synthesis-free method for PET imaging of brown adipose tissue (BAT) and translocat

183 irst effective (68)Ga compounds reported for PET imaging of CA IX.

184 PET imaging of CA125 expression by ovarian cancer cells

185 onal antibody that has shown promise for the PET imaging of cancers expressing carbohydrate antigen 1

186 s changes in neural circuitry (measured with PET imaging of cerebral glucose metabolism at baseline a

187 is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic a

188 Combining in vivo PET imaging of dopamine synthesis capacity, fMRI, and a

189 PET imaging of EAE and control mice was performed 1, 4,

190 LUT5 represents an alternative biomarker for PET imaging of hexose metabolism in BC.

191 ising candidate for preclinical and clinical PET imaging of hNIS expression and thyroid-related disea

192 re, we sought to optimize noninvasive immuno-PET imaging of human programmed death-ligand 1 (PD-L1) e

193 ble of standardizing quantitative changes in PET imaging of patients with metastatic prostate cancer

194 PET imaging of proliferation, angiogenesis, and DNA dama

195 PET imaging of tau pathology in Alzheimer disease may be

196 ibited FVII (FVIIai) labeled with (64)Cu for PET imaging of TF expression.

197 )F-DPA-714 is a second-generation tracer for PET imaging of the 18-kDa translocator protein (TSPO), a

198 c 4T1luc tumors, allowing for the successful PET imaging of the tumors as early as 2 h after injectio

199 f this study was to explore the potential of PET imaging of the urokinase-type plasminogen activator

200 F-GP1 is an (18)F-labeled small molecule for PET imaging of thrombi.

201 Hence, the time point for [(18)F]FLT-PET imaging of tumor response to gemcitabine is of cruci

202 (64)Cu-NOTA-FVIIai is well suited for PET imaging of tumor TF expression, and imaging is capab

203 ation of an antibody-based imaging agent for PET imaging of VEGFR-2 expression in vivo.

204 ting of TF for positron emission tomography (PET) imaging of pancreatic cancer.

205 Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO) h

206 e studies used positron emission tomography (PET) imaging of the TSPO microglial marker and found inc

207 Baseline PET imaging parameters, including SUV, proliferative vol

208 (68)Ga-PSMA HBED-CC PET imaging performed significantly superior to morpholo

209 F-TFB, (18)F-BF4 (-)) has shown promise as a PET imaging probe for NIS, the current synthesis method

210 C-radiolabeled sarcosine was tested as a new PET imaging probe in comparison with (11)C-choline in 2

211 We successfully developed 4-(11)C-MBZA as a PET imaging probe, displaying properties advantageous ov

212 We successfully developed 4-(11)C-MBZA as a PET imaging probe, displaying properties advantageous ov

213 We designed novel PET imaging probes for the murine and human granzyme B i

214 at early stages, and newer, more sensitive, PET imaging probes need to be developed.

215 PET imaging provides information critical for successful

216 tate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-bo

217 he impact of different heating conditions on PET imaging quantification was evaluated.

218 lective microglial markers are available for PET imaging, quantification of cytokines and other infla

219 hould be further studied to evaluate it as a PET imaging radiotracer.

220 Before undertaking (68)Ga-PSMA PET imaging, referring medical specialists completed a q

221 nflammation using (18)F-FAZA and (18)F-FMISO PET imaging represents a promising new tool for uncoveri

222 f this technique in myelofibrosis, (18)F-FLT PET imaging results were compared with bone marrow histo

223 r samples and correlated with (18)F-AH113804 PET imaging results.

224 After being labeled with (64)Cu, PET imaging revealed specific and prominent uptake of (6

225 (89)Zr-NRep PET imaging reveals remarkable accumulation heterogeneit

226 PET imaging showed specific tracer accumulation at plaqu

227 In vivo PET imaging showed specific uptake in PSMA-expressing tu

228 a isotope) or optimal nuclide properties for PET imaging (slightly favoring the (18)F isotope).

229 We have developed a PET imaging strategy for DLBCL that targets poly[ADP rib

230 may be an attractive addition to the current PET imaging strategy to differentiate inflammation from

231 rotein expression levels in combination with PET imaging studies for functional characterization of G

232 ue of PF-367 was synthesized and preliminary PET imaging studies in non-human primates confirmed that

233 as well as in vivo biodistribution and brain PET imaging studies in wildtype and mGluR2 knockout rats

234 In subsequent non-human primate (NHP) PET imaging studies, [(18)F]8 showed rapid brain uptake

235 nifest and premanifest HDGECs as measured by PET imaging studies.

236 he past years, positron emission tomography (PET) imaging studies have investigated striatal molecula

237 F-Mefway) for positron emission tomography (PET) imaging studies of serotonin 5-HT1A receptors which

238 estigations indicated that the presence of a PET imaging study demonstrating abnormalities in individ

239 By combining data from a PET imaging study using (89)Zr-labeled bevacizumab and a

240 herapeutic and positron emission tomography (PET) imaging target in cancer.

241 of the potential of combining a multitracer PET imaging technique and a longitudinal protocol applie

242 cterize a specific small-molecule tracer for PET imaging that binds with high affinity to GPIIb/IIIa

243 uthors have combined multiparametric MRI and PET imaging to address the important issue of intratumor

244 ents were examined using [(11) C]PBR28 brain PET imaging to assess brain immune cell activation.

245 view should be below 3.3 GBq at the time of PET imaging to avoid deadtime losses for this scanner.

246 monstrate the utility of noninvasive in vivo PET imaging to dynamically track T-cell checkpoint recep

247 We used (11)C-metoclopramide PET imaging to elucidate the kinetic impact of transport

248 nducted a first-in-human study of (18)F-MFBG PET imaging to evaluate the safety, feasibility, pharmac

249 11-labeled Pittsburgh Compound B ([11C]PiB) PET imaging to measure amyloid burden, and structural ma

250 Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11-labeled Pit

251 In this study, we used PET imaging to study the pharmacokinetics and tumor deli

252 oxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapte

253 oxyglucose positron emission tomography (FDG-PET) imaging to understand the neural systems governing

254 of approximately 10 nm, as measured by using PET imaging tracing.

255 linical profiles, structural MRI and amyloid PET imaging typical for svPPA, FTP signal was unexpected

256 Conclusion: Dynamic PET imaging under baseline and blocking conditions deter

257 Dynamic PET imaging under baseline and blocking conditions deter

258 can be clearly visualized using small-animal PET imaging up to 72 h after injection.

259 c accumulation in TF-positive BXPC-3 tumors, PET imaging using (89)Zr-Df-ALT-836 promises to open new

260 PET imaging using (89)Zr-DFO-mAb-B43.13 (DFO is desferri

261 In this study, uPAR PET imaging using a (68)Ga-labeled version of the uPAR-t

262 PET imaging using aged, female, retired breeder rats sho

263 coma, or cancer of unknown primary underwent PET imaging using the novel CXCR4 nuclear probe (68)Ga-p

264 Human PET imaging using the second-generation TSPO radiotracer

265 ne ((18)F-FLT) is a proliferation tracer for PET imaging valuable in the monitoring of disease progre

266 In vivo PET imaging visualized rapid excretion of the administra

267 TPM mouse model, suggesting that (64)Cu-GTSM PET imaging warrants clinical evaluation as a diagnostic

268 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET imaging in 42

269 Longitudinal in vivo PET imaging was performed at 1, 4, 15, and 36 h after in

270 PET imaging was performed for (68)Ga-aquibeprin and the

271 (18)F-AV-1451 PET imaging was performed on 43 subjects (5 young HCs, 2

272 Dosimetry from multi-time-point PET imaging was performed with OLINDA/EXM.

273 tly after administration of 3 MBq/kg of FCH, PET imaging was performed, followed by T1- and T2-weight

274 Dynamic whole-body PET imaging was used to determine the insulin-mediated (

275 PET imaging was used to evaluate the whole-body distribu

276 ntify a more suitable probe for clinical dCK PET imaging, we compared the selectivity of two candidat

277 Here, using PET imaging, we investigated whether lung cancer PDXs re

278 rment n = 116) with standardized MRI and PiB-PET imaging were included.

279 In vivo biodistribution and small-animal PET imaging were performed in mice bearing B16F1 melanom

280 Pharmacokinetics and PET imaging were studied in nude mice bearing rat Ins-1E

281 particle-based positron emission tomography (PET) imaging, whereas its accuracy remains questionable.

282 PET imaging, whole-body probe counts, and blood draws we

283 erphosphorylated tau in vivo, results of tau PET imaging will likely serve as a key biomarker that li

284 PET imaging with (18)F-DCFBC, a small-molecule PSMA-targ

285 pathology were obtained through small-animal PET imaging with (18)F-FDG, (18)F-peripheral benzodiazep

286 PET imaging with (18)F-MFBG allows for same-day imaging

287 ficking in a transgenic mouse model of AD by PET imaging with (64)Cu, to determine its potential as a

288 tly published biodistribution data of immuno-PET imaging with (64)Cu-cetuximab and of small-animal SP

289 Longitudinal PET imaging with (64)Cu-NOTA-FVIIai showed a tumor uptak

290 Using PET imaging with a radiotracer specific for the serotoni

291 disease; it is the first example of in vivo PET imaging with a tracer containing an S-(18)F bond.

292 Longitudinal quantitative small-animal PET imaging with an arterial input function can be perfo

293 Dynamic PET imaging with arterial blood sampling was performed i

294 a first look at the relationship between Tau-PET imaging with F(18)-AV1451 and functional connectivit

295 rther validation in large samples, (18)F-FDG PET imaging with network analysis may provide a viable b

296 By combining PET imaging with the D3-preferring radioligand [(11)C]-(

297 c resonance-positron emission tomography (MR-PET) imaging with (11) C-PBR28, we quantified expression

298 re we describe positron emission tomography (PET) imaging with (18)F-Macroflor, a modified polyglucos

299 Positron emission tomography (PET) imaging with radiotracers that target translocator

300 = 3), we used positron emission tomography (PET) imaging with the radioligand [(11)C]AZ10419369 admi